Hello, Guest!

Latest News Mentioning Food and Drug Administration

Advanced Search
Showing 1-10 of 68

SRI International has secured a seven-year, $150 million contract from the National Institutes of Health to provide development services for candidate HIV prevention products from investigator-initiated studies or from partnerships with other companies and organizations. SRI said Tuesday its biosciences division will manufact...

Brooke Patterson, formerly vice president and deputy general manager of FEI Systems, has been appointed senior VP for government services at Norfolk, Virginia-based healthcare management and information technology consulting firm ARDX. ARDX said Tuesday that Patterson will oversee the company’s efforts to ex...

The Department of Health and Human Services has awarded Emergent BioSolutions a five-year, $198.7 million contract to further mature the development of an anthrax vaccine in preparation for a Food and Drug Administration license. The HHS office of the assistant secretary for preparedness and response’s Biomedical Advanced Research ...

Altimmune has received a potential five-year, $120.2 million contract from the Biomedical Advanced Research and Development Authority to conduct clinical trials on an experimental vaccine against anthrax. The Gaithersburg, Maryland-based immunotherapeutic company will test its NasoShield intranasal anthrax vaccine through Pha...

TYSONS CORNER, VA, Aug. 3, 2016 — Siemens has received emergency use authorization from the Food and Drug Administration for the company’s VERSANT Zika RNA 1.0 Assay Kit that aims to detect the presence of the Zika virus in plasma, blood and urine samples, ExecutiveB...

Information Innovators Inc. has secured a potential five-year, $100 million contract from the Food and Drug Administration to provide web content management system support services. Triple-i said Tuesday the new blanket purchase agreement seeks to expand the services the company...

The Biomedical Advanced Research and Development Authority has awarded Emergent BioSolutions (NYSE: EBS) a potential $21.9 million task order to develop and produce a vaccine against Zika virus for use in the first phase of a clinical trial. The company said Monday the order has a base period of 30 months worth $17.9 million and covers...